Screener
Cogent Biosciences, Inc. COGT Research And Development Personnel Related — Operating Income
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating Expenses | ||
| Late-stage development | $28,102 | $28,097 |
| Early-stage, preclinical and discovery programs | 13,975 | 9,778 |
| R&D personnel related | 18,047 | 14,874 |
| Research and development software, facilities and other strategic support | 5,734 | 4,425 |
| Other operational infrastructure and advisory support | 20,215 | 7,121 |
| Stock-based compensation expense | 16,908 | 10,008 |
| Depreciation expense | 626 | 640 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Cogent Biosciences, Inc.'s research and development personnel related — operating income?
- Cogent Biosciences, Inc. (COGT) reported research and development personnel related — operating income of $18.05M in Q1 2026.
- How has Cogent Biosciences, Inc.'s research and development personnel related — operating income changed year-over-year?
- Cogent Biosciences, Inc.'s research and development personnel related — operating income increased by 21.3% year-over-year, from $14.87M to $18.05M.
- What is the long-term trend for Cogent Biosciences, Inc.'s research and development personnel related — operating income?
- Over 3 years (2022 to 2025), Cogent Biosciences, Inc.'s research and development personnel related — operating income has grown at a 34.2% compound annual growth rate (CAGR), from $26.42M to $63.88M.
- What does research and development personnel related — operating income mean?
- This metric represents the operating loss specifically attributable to personnel-related expenses within the research and development function. It captures the financial impact of human capital investment, including salaries, benefits, and stock-based compensation for staff dedicated to advancing the company's clinical pipeline. Monitoring this figure helps investors assess the cost structure of the company's scientific workforce and the efficiency of its R&D resource allocation.
Ask your AI about Cogent Biosciences, Inc.'s research and development personnel related — operating income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude